These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 20226299)

  • 1. The opportunity costs of screening children for asthma.
    McElligott S; Polsky D
    J Allergy Clin Immunol; 2010 Mar; 125(3):651-2. PubMed ID: 20226299
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
    Lin OS; Keeffe EB; Sanders GD; Owens DK
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma.
    Swigonski NL; Kuhlenschmidt HL; Bull MJ; Corkins MR; Downs SM
    Pediatrics; 2006 Aug; 118(2):594-602. PubMed ID: 16882812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of screening for HIV.
    da Silveira E
    N Engl J Med; 2005 May; 352(20):2137-9; author reply 2137-9. PubMed ID: 15906436
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of screening for latent tuberculosis infection.
    Taylor Z
    Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S127-33. PubMed ID: 11144542
    [No Abstract]   [Full Text] [Related]  

  • 9. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program.
    van den Boom G; Rutten-van Mölken MP; Folgering H; van Weel C; van Schayck CP
    Prev Med; 2000 Apr; 30(4):302-8. PubMed ID: 10731459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.
    Kumar M; Birch S; Maturana A; Gafni A
    Health Policy; 2006 Jul; 77(2):233-43. PubMed ID: 16126300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of FE(NO) measurement in diagnosis and 1-year management of asthma in Germany.
    Berg J; Lindgren P
    Respir Med; 2008 Feb; 102(2):219-31. PubMed ID: 18029165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
    Gerson L; Lin OS
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
    Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of screening and correcting refractive errors in school children in Africa, Asia, America and Europe.
    Baltussen R; Naus J; Limburg H
    Health Policy; 2009 Feb; 89(2):201-15. PubMed ID: 18621429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
    Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK
    Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting calculations aside.
    Meyer CR
    Minn Med; 2003 Dec; 86(12):2. PubMed ID: 14719607
    [No Abstract]   [Full Text] [Related]  

  • 17. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health economics analysis of colorectal screening].
    Boncz I; Sebestyén A; Dózsa C; Pál M; Sándor J; Palásti J; Betlehem J; Ember I
    Magy Onkol; 2004; 48(2):111-5. PubMed ID: 15351803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Critical evaluation of a cost-effectiveness analysis].
    Sendi PP; Bucher HC; Steurer J
    Praxis (Bern 1994); 1998 Dec; 87(49):1695-702. PubMed ID: 9887670
    [No Abstract]   [Full Text] [Related]  

  • 20. Examining the cost-effectiveness of cancer screening promotion.
    Andersen MR; Urban N; Ramsey S; Briss PA
    Cancer; 2004 Sep; 101(5 Suppl):1229-38. PubMed ID: 15316909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.